Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 685 Carcinoma, Non-Small-Cell Lung 328 Neoplasms 170 Breast Neoplasms 166 Lung Neoplasms 158 Urinary Bladder Neoplasms 157 Neoplasm Metastasis 140 Cholangiocarcinoma 113 Ovarian Neoplasms 106 Biliary Tract Neoplasms 95 Lymphoma, Large B-Cell, Diffuse 73 Nasopharyngeal Carcinoma 71 Lymphoma 66 Sarcoma 63 Recurrence 62 Gallbladder Neoplasms 61 Carcinoma, Transitional Cell 56 Triple Negative Breast Neoplasms 54 Hodgkin Disease 52 Colorectal Neoplasms 49 Lymphoma, Non-Hodgkin 48 Fallopian Tube Neoplasms 48 Adenocarcinoma 45 Bile Duct Neoplasms 40 Carcinoma, Ovarian Epithelial 31 Non-Muscle Invasive Bladder Neoplasms 30 Uterine Cervical Neoplasms 28 Carcinoma 28 Unspecified Adult Solid Tumor, Protocol Specific 27 Adenocarcinoma of Lung 27

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × Gemcitabine × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡